Vivos Therapeutics Inc (VVOS) FY2025Q3 Earning Prediction
Vivos Therapeutics Inc (VVOS) is set to release its earnings performance on 11/19 ET in After Hours trading. Consensus forecasts predict a revenue of 4.71M and an earnings per share (EPS) of -0.53 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
VVOS Transcript
The earnings call presents a mixed picture. While there is a significant revenue growth and expansion plans, concerns remain about cash flow and profitability due to ongoing net losses and high expenses. The Q&A section reveals optimism for future growth but lacks specific timelines for breakeven, which could worry investors. The slight decrease in gross margin and the substantial net loss further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the lack of clear guidance tempers the positive elements.
The earnings call reveals several concerns: a 6% revenue decline, increased operating losses, high acquisition costs, and cash flow challenges. Despite potential long-term benefits from acquisitions and strategic alliances, the immediate financial strain and reliance on debt raise red flags. No positive shareholder return plan was discussed, and the Q&A section did not clarify management's responses. Without a market cap, the stock's volatility is uncertain, but the financial issues suggest a negative short-term outlook.
The earnings call reveals mixed financial performance, with declining total revenue and gross margins, and an increase in operating loss. While there are positive developments, such as the SCN acquisition and potential revenue growth, the company's financial health is concerning, with significant cash burn and increased operational expenses. The Q&A section highlighted management's vague responses regarding financial impact, raising concerns. Given these factors, the stock price is likely to react negatively in the short term, with a potential decline between -2% to -8%.
Despite challenges, Vivos shows potential for growth through strategic acquisitions and new business models. However, financial risks, cash flow issues, and competitive pressures temper optimism. The SCN acquisition could boost revenue, but operational costs and integration risks remain. The Q&A highlights both the potential and uncertainties of partnerships. Overall, mixed financial results and cautious guidance suggest a neutral outlook.
VVOS Report
Frequently Asked Questions
What is the Vivos Therapeutics Inc FY2025Q3 Earnings Release Date and Time?
Vivos Therapeutics Inc (VVOS) is scheduled to release its FY2025Q3 earnings report onNov 19, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Vivos Therapeutics Inc FY2025Q3 Revenue and EPS?
Analysts' consensus predicts 4.71M in revenue and an EPS of -0.53 for Vivos Therapeutics Inc's FY2025Q3.
What Does Intellectia's AI Predict for Vivos Therapeutics Inc FY2025Q3 Earnings?
Intellectia's exclusive AI algorithms forecast a forVivos Therapeutics Inc's FY2025Q3 earnings, with a prediction date of Nov 19, 2025. Vivos Therapeutics Inc
How Can I Use This Earnings Prediction to Trade VVOS Stock?
Leverage Intellectia's AI forecast to position trades ahead of theNov 19, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Vivos Therapeutics Inc FY2025Q3?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
